Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $7.43.

Several research analysts recently commented on TRVI shares. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a research note on Tuesday. Raymond James assumed coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set an “outperform” rating and a $9.00 price objective for the company. B. Riley reissued a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a report on Monday, October 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research note on Friday, October 4th.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.76, for a total value of $51,501.60. Following the sale, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.76, for a total value of $51,501.60. Following the sale, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $644,205.26. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,355 shares of company stock worth $116,663. Insiders own 24.37% of the company’s stock.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently added to or reduced their stakes in TRVI. Price T Rowe Associates Inc. MD bought a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $47,000. Hsbc Holdings PLC purchased a new position in shares of Trevi Therapeutics in the second quarter worth $61,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after acquiring an additional 11,450 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Trevi Therapeutics in the third quarter worth approximately $78,000. Finally, American Century Companies Inc. grew its holdings in shares of Trevi Therapeutics by 17.1% in the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after acquiring an additional 7,902 shares during the period. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Down 0.6 %

TRVI stock opened at $3.21 on Friday. Trevi Therapeutics has a twelve month low of $0.97 and a twelve month high of $4.00. The company has a market cap of $226.10 million, a P/E ratio of -9.44 and a beta of 0.97. The business has a fifty day moving average of $3.12 and a 200-day moving average of $2.89.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter in the prior year, the business earned ($0.07) EPS. As a group, equities research analysts anticipate that Trevi Therapeutics will post -0.47 earnings per share for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.